Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A newly identified epigenetic modifier increases fetal hemoglobin in preclinical studies.

Original publication

DOI

10.1126/science.adq3757

Type

Journal article

Journal

Science (New York, N.Y.)

Publication Date

07/2024

Volume

385

Pages

27 - 28

Addresses

Laboratory of Gene Regulation, MRC Weatherall Institute of Molecular Medicine, and Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.

Keywords

Animals, Humans, Mice, Anemia, Sickle Cell, Fetal Hemoglobin, Antisickling Agents, Epigenesis, Genetic, Drug Discovery